<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C41B3726-9589-48C4-A323-7A6B005207BA"><gtr:id>C41B3726-9589-48C4-A323-7A6B005207BA</gtr:id><gtr:name>Cyprotex</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EFA0BB57-88E2-460B-A804-020C507F0CF3"><gtr:id>EFA0BB57-88E2-460B-A804-020C507F0CF3</gtr:id><gtr:name>Research Complex at Harwell</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2ECA69AA-2FF9-4EDF-AE48-E442D561809F"><gtr:id>2ECA69AA-2FF9-4EDF-AE48-E442D561809F</gtr:id><gtr:name>Edinburgh Bioquarter</gtr:name><gtr:address><gtr:line1>47 Little France Crescent</gtr:line1><gtr:postCode>EH16 4TJ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A048B26F-E403-43A9-B7A7-0DC49210E846"><gtr:id>A048B26F-E403-43A9-B7A7-0DC49210E846</gtr:id><gtr:name>Academy of Sciences of the Republic of Tajikistan</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3C59EF51-0767-4799-A30B-DBD8CAC459CF"><gtr:id>3C59EF51-0767-4799-A30B-DBD8CAC459CF</gtr:id><gtr:name>Dexcom</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C687B40-4780-4290-A0E0-39EC669D33CF"><gtr:id>9C687B40-4780-4290-A0E0-39EC669D33CF</gtr:id><gtr:name>Muhimbili University of Health and Allied Sciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BE81F27C-9DA4-4DF5-B433-E992845A5385"><gtr:id>BE81F27C-9DA4-4DF5-B433-E992845A5385</gtr:id><gtr:name>Merieux Institute (Institut M?rieux)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9F394551-39F2-4E03-B116-0204C0274D2C"><gtr:id>9F394551-39F2-4E03-B116-0204C0274D2C</gtr:id><gtr:name>Ministry of Health</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/23454317-ADC4-4369-A212-BF0802191E59"><gtr:id>23454317-ADC4-4369-A212-BF0802191E59</gtr:id><gtr:name>Domainex</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91CF4E3B-0C41-4B40-8FFA-522B4513C5E8"><gtr:id>91CF4E3B-0C41-4B40-8FFA-522B4513C5E8</gtr:id><gtr:name>Le Dantec Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/695C8934-7703-4C7A-8271-2DE16281D4E9"><gtr:id>695C8934-7703-4C7A-8271-2DE16281D4E9</gtr:id><gtr:name>Xeptagen Ltd, Venice, Italy</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0FA55A50-871F-4EB0-AD0D-26D1AF99C603"><gtr:id>0FA55A50-871F-4EB0-AD0D-26D1AF99C603</gtr:id><gtr:name>Bio Products Laboratory Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E99485A4-D214-4130-8F68-73848BB02CBD"><gtr:id>E99485A4-D214-4130-8F68-73848BB02CBD</gtr:id><gtr:name>Peakdale Molecular</gtr:name><gtr:address><gtr:line1>Frith Knoll Road</gtr:line1><gtr:line3>Chapel-en-le-frith</gtr:line3><gtr:postCode>SK23 0PG</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/16A3D8C3-5A17-4BF4-9EBE-0F31C2B6BF74"><gtr:id>16A3D8C3-5A17-4BF4-9EBE-0F31C2B6BF74</gtr:id><gtr:name>West African College of Physicians</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/97889367-1389-4ADD-96A8-E8D3579259E8"><gtr:id>97889367-1389-4ADD-96A8-E8D3579259E8</gtr:id><gtr:name>University of Jos</gtr:name><gtr:address><gtr:line1>PMB 2084</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/28853A70-BCE0-4AAC-97F9-9CF076C218DD"><gtr:id>28853A70-BCE0-4AAC-97F9-9CF076C218DD</gtr:id><gtr:name>Dundee Model Railway Club</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/67B34D05-3A52-4A09-8FF9-F2398D60E246"><gtr:id>67B34D05-3A52-4A09-8FF9-F2398D60E246</gtr:id><gtr:name>University of Surrey</gtr:name><gtr:address><gtr:line1>Registry</gtr:line1><gtr:line2>Stag Hill</gtr:line2><gtr:line4>Guildford</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU2 7XH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9040505D-32E9-4685-AE24-6609146B7092"><gtr:id>9040505D-32E9-4685-AE24-6609146B7092</gtr:id><gtr:name>Biofocus</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF50F5F2-9CE2-48EC-8A5A-409480A56BA8"><gtr:id>FF50F5F2-9CE2-48EC-8A5A-409480A56BA8</gtr:id><gtr:name>Royal Victoria Teaching Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/348F55A7-05FA-4669-A3AB-0C2E6844DDB7"><gtr:id>348F55A7-05FA-4669-A3AB-0C2E6844DDB7</gtr:id><gtr:name>Cellnovo</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1A60B063-E58F-4072-A2EA-8474BE302464"><gtr:id>1A60B063-E58F-4072-A2EA-8474BE302464</gtr:id><gtr:name>International Agency for Research on Cancer (IARC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/41CFC9DF-9D6C-47D3-9C2D-973A88BF00A1"><gtr:id>41CFC9DF-9D6C-47D3-9C2D-973A88BF00A1</gtr:id><gtr:name>Thies Medical School</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C"><gtr:id>FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C</gtr:id><gtr:name>University of Alabama at Birmingham</gtr:name><gtr:address><gtr:line1>1720 2nd Avenue South</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:line5>Alabama 35294-0017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C41B3726-9589-48C4-A323-7A6B005207BA"><gtr:id>C41B3726-9589-48C4-A323-7A6B005207BA</gtr:id><gtr:name>Cyprotex</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EFA0BB57-88E2-460B-A804-020C507F0CF3"><gtr:id>EFA0BB57-88E2-460B-A804-020C507F0CF3</gtr:id><gtr:name>Research Complex at Harwell</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2ECA69AA-2FF9-4EDF-AE48-E442D561809F"><gtr:id>2ECA69AA-2FF9-4EDF-AE48-E442D561809F</gtr:id><gtr:name>Edinburgh Bioquarter</gtr:name><gtr:address><gtr:line1>47 Little France Crescent</gtr:line1><gtr:postCode>EH16 4TJ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A048B26F-E403-43A9-B7A7-0DC49210E846"><gtr:id>A048B26F-E403-43A9-B7A7-0DC49210E846</gtr:id><gtr:name>Academy of Sciences of the Republic of Tajikistan</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3C59EF51-0767-4799-A30B-DBD8CAC459CF"><gtr:id>3C59EF51-0767-4799-A30B-DBD8CAC459CF</gtr:id><gtr:name>Dexcom</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C687B40-4780-4290-A0E0-39EC669D33CF"><gtr:id>9C687B40-4780-4290-A0E0-39EC669D33CF</gtr:id><gtr:name>Muhimbili University of Health and Allied Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BE81F27C-9DA4-4DF5-B433-E992845A5385"><gtr:id>BE81F27C-9DA4-4DF5-B433-E992845A5385</gtr:id><gtr:name>Merieux Institute (Institut M?rieux)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9F394551-39F2-4E03-B116-0204C0274D2C"><gtr:id>9F394551-39F2-4E03-B116-0204C0274D2C</gtr:id><gtr:name>Ministry of Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/23454317-ADC4-4369-A212-BF0802191E59"><gtr:id>23454317-ADC4-4369-A212-BF0802191E59</gtr:id><gtr:name>Domainex</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91CF4E3B-0C41-4B40-8FFA-522B4513C5E8"><gtr:id>91CF4E3B-0C41-4B40-8FFA-522B4513C5E8</gtr:id><gtr:name>Le Dantec Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/695C8934-7703-4C7A-8271-2DE16281D4E9"><gtr:id>695C8934-7703-4C7A-8271-2DE16281D4E9</gtr:id><gtr:name>Xeptagen Ltd, Venice, Italy</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0FA55A50-871F-4EB0-AD0D-26D1AF99C603"><gtr:id>0FA55A50-871F-4EB0-AD0D-26D1AF99C603</gtr:id><gtr:name>Bio Products Laboratory Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E99485A4-D214-4130-8F68-73848BB02CBD"><gtr:id>E99485A4-D214-4130-8F68-73848BB02CBD</gtr:id><gtr:name>Peakdale Molecular</gtr:name><gtr:address><gtr:line1>Frith Knoll Road</gtr:line1><gtr:line3>Chapel-en-le-frith</gtr:line3><gtr:postCode>SK23 0PG</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/16A3D8C3-5A17-4BF4-9EBE-0F31C2B6BF74"><gtr:id>16A3D8C3-5A17-4BF4-9EBE-0F31C2B6BF74</gtr:id><gtr:name>West African College of Physicians</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/97889367-1389-4ADD-96A8-E8D3579259E8"><gtr:id>97889367-1389-4ADD-96A8-E8D3579259E8</gtr:id><gtr:name>University of Jos</gtr:name><gtr:address><gtr:line1>PMB 2084</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/28853A70-BCE0-4AAC-97F9-9CF076C218DD"><gtr:id>28853A70-BCE0-4AAC-97F9-9CF076C218DD</gtr:id><gtr:name>Dundee Model Railway Club</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/67B34D05-3A52-4A09-8FF9-F2398D60E246"><gtr:id>67B34D05-3A52-4A09-8FF9-F2398D60E246</gtr:id><gtr:name>University of Surrey</gtr:name><gtr:address><gtr:line1>Registry</gtr:line1><gtr:line2>Stag Hill</gtr:line2><gtr:line4>Guildford</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU2 7XH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9040505D-32E9-4685-AE24-6609146B7092"><gtr:id>9040505D-32E9-4685-AE24-6609146B7092</gtr:id><gtr:name>Biofocus</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF50F5F2-9CE2-48EC-8A5A-409480A56BA8"><gtr:id>FF50F5F2-9CE2-48EC-8A5A-409480A56BA8</gtr:id><gtr:name>Royal Victoria Teaching Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/348F55A7-05FA-4669-A3AB-0C2E6844DDB7"><gtr:id>348F55A7-05FA-4669-A3AB-0C2E6844DDB7</gtr:id><gtr:name>Cellnovo</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1A60B063-E58F-4072-A2EA-8474BE302464"><gtr:id>1A60B063-E58F-4072-A2EA-8474BE302464</gtr:id><gtr:name>International Agency for Research on Cancer (IARC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/41CFC9DF-9D6C-47D3-9C2D-973A88BF00A1"><gtr:id>41CFC9DF-9D6C-47D3-9C2D-973A88BF00A1</gtr:id><gtr:name>Thies Medical School</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C"><gtr:id>FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C</gtr:id><gtr:name>University of Alabama at Birmingham</gtr:name><gtr:address><gtr:line1>1720 2nd Avenue South</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:line5>Alabama 35294-0017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E5AC7F34-4BD1-4120-9F04-E44157ED4C2E"><gtr:id>E5AC7F34-4BD1-4120-9F04-E44157ED4C2E</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Weber</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12015"><gtr:id>89A994FB-742D-4FAE-9FF5-955CB8D8761E</gtr:id><gtr:title>Confidence in Concept 2012 - Imperial</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12015</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2015-07-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>700000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Domainex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Edward, M - P47173 - Domainex</gtr:description><gtr:id>8B32172A-BE66-4E57-BCCE-00EBED05DF2B</gtr:id><gtr:impact>Azithromycin augments RV-induced type I IFN and type III IFNs via interaction with MAVS. Michael R Edwards Oral Presentation, XVI International Symposium on Respiratory Viral Infections Seoul, Korea 2014. 
http://www.themacraefoundation.org/wp-content/uploads/2013/08/Final-Program-2.pdf 

Novel inhibitors of TGF-? activating kinase (TAK1) uncouple beneficial anti-viral innate immunity from harmful virus-induced pro-inflammatory responses in models of rhinovirus infection. Michael R. Edwards, Katie Chapman, Jennifer J. Haas, Louise Slater, Albert Jaxa-Chamiec, Caroline Low, Hayley Cordingley, Roberto Solari, Sebastian L. Johnston Catherine Tralau-Stewart. Poster Presentation, American Thoracic Society, San Diego, USA 2014. 
The collaboration is multi-disciplinary; cell biology, immunology, drug discovery and chemistry are the various disciplines involved.</gtr:impact><gtr:outcomeId>544f709e65f270.00959931-1</gtr:outcomeId><gtr:partnerContribution>Domainex screened Imperial in-house small molecule library</gtr:partnerContribution><gtr:piContribution>Imperial provided in-house small molecule library</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merieux Institute (Institut M?rieux)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Taylor-Robinson - ICiC 1 - Prolifica (IMF)</gtr:description><gtr:id>1C1C17D4-A69B-4FE9-9063-DA8E2E0DC6EF</gtr:id><gtr:impact>Not yet - ongoing</gtr:impact><gtr:outcomeId>56cae3286ace75.71407168-1</gtr:outcomeId><gtr:partnerContribution>Financial funding - Ongoing Institut Merieux funding until August 2016 (2 years) for 100,000 euros per year to further fund the liver cancer biomarker work in Africa</gtr:partnerContribution><gtr:piContribution>The Taylor-Robinson group have ongoing liver cancer biomarker work in Africa to develop a low cost urinary diagnostic which is being funded by Institut Merieux. The monies have facilitated collection of samples by the team in Nigeria, Gambia and Senegal and the analysis of samples at Imperial College London</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>Gambia, Republic of the</gtr:country><gtr:department>MRC Unit, The Gambia</gtr:department><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>C74BFF49-3D6D-4803-A6EC-B38FA2222D4E</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-2</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>E810661F-AB16-4E53-9CFF-3CBFAE951F63</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-10</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xeptagen Ltd, Venice, Italy</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>2945F042-8681-4505-97D3-45B457608276</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-9</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bio Products Laboratory Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Quinlan - ICiC1 - BPL</gtr:description><gtr:id>C2540011-B7F5-4774-B8F2-D6BB22CADC67</gtr:id><gtr:impact>A device in the form a filter to remove haemoglobin and related products from blood for the incorporation in extracorporeal circuits.</gtr:impact><gtr:outcomeId>5460aa0690be62.85509962-1</gtr:outcomeId><gtr:partnerContribution>Gregory Quinlan's team are about to send them a technical report including a description our expectations from BPL. This collaboration was initiated prior to the ICiC award but is important to Dr Quinlan's ICiC1 project.</gtr:partnerContribution><gtr:piContribution>BPL are the providers of Haptoglobin which is utilised as a component of the filter device. Gregory Quinlan's team actually have a CDA in place with BPL going back seven years (facilitated though UCL).</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Giamas - P47199 - ProfNC</gtr:description><gtr:id>1CF0091F-196F-4324-A700-C9F5E01F1EBC</gtr:id><gtr:impact>Yes this is a multi-disciplinary collaboration: Basic research (molecular, cell biology) along with structural biology.</gtr:impact><gtr:outcomeId>544fc5d43c48d6.04035868-1</gtr:outcomeId><gtr:partnerContribution>This LMTK3 protein is currently being used by our collaborator Professor Naomi Chayen (Imperial College) in crystallography assays</gtr:partnerContribution><gtr:piContribution>Generated more pure and conformationally accurate LMTK3 protein that has been tested positive for kinase activity in in vitro kinase assays</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peakdale Molecular</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Snelgrove - Peakdale Molecular</gtr:description><gtr:id>C1AC45CE-9AD5-4B91-9E64-ED95DE6C5F5A</gtr:id><gtr:impact>The collaboration has been successful in the synthesis of novel compounds that show distinction between the dual activities of LTA4H, as well as the production of current pharmaceutical LTA4H inhibitors (to which we will be comparing our compounds ).</gtr:impact><gtr:outcomeId>5458a2a2832ef5.48127056-1</gtr:outcomeId><gtr:partnerContribution>In essence, we inform them of the compounds that we would like synthesized and then subsequently pay them to make them</gtr:partnerContribution><gtr:piContribution>We have formed a collaboration with Peakdale Molecular for the outsourcing of drug synthesis. Whilst there is an on-going narrative between ourselves and Peakdale about the drug synthesis pathways, they are largely providing a service.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Life Sciences</gtr:department><gtr:description>Snelgrove - ICiC1+2 - DrSH</gtr:description><gtr:id>7452C4C8-1C34-4101-9260-DD8DCAA5B743</gtr:id><gtr:impact>Successful generation of X-ray crystallography structures of lead compounds bound within active site of LTA4H. These will form part of a manuscript currently in preparation. They were also part of an unsuccessful application to the Wellcome Trust seeding drug discovery scheme and will form part of an application to the MRC DPFS scheme.</gtr:impact><gtr:outcomeId>56d82bf647de02.43879804-1</gtr:outcomeId><gtr:partnerContribution>Expertise in X-ray crystallography - conducted experiments and analysis.</gtr:partnerContribution><gtr:piContribution>Generation / provision of novel Leukotriene A4 hydrolase (LTA4H) modulators and recombinant LTA4H enzyme.
Knowledge of LTA4H active site and Structure-Activity Relationship (SAR) studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ministry of Health</gtr:collaboratingOrganisation><gtr:country>Rwanda, Republic of</gtr:country><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>5BF1FFEA-4BAE-4775-9C07-55C15F44750D</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-8</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Diego (UCSD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Edwards - P47173 - UCSD</gtr:description><gtr:id>F4354672-9704-4694-842A-723860E364AF</gtr:id><gtr:impact>The collaboration is multi-disciplinary; cell biology, immunology, drug discovery and chemistry are the various disciplines involved.</gtr:impact><gtr:outcomeId>54524bc9d17eb5.09299807-1</gtr:outcomeId><gtr:partnerContribution>Mike Pirrung &amp;amp; Nicholas Webster at Uni of California, San Diego - provided library of novel asterrquinones based around the structure of demethylasterrquinone (under MTA)</gtr:partnerContribution><gtr:piContribution>Edwards team has identified demethylasterrquinone as a novel inhibitor of TAK1 and NF-?B</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Surrey</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Oliver ICiC - University of Surrey</gtr:description><gtr:id>4F0F1DCD-7096-4B33-A8AA-CB3FD9D5A4B5</gtr:id><gtr:impact>Obtaining gold coated devices of higher quality</gtr:impact><gtr:outcomeId>5453671deb7958.61758667-1</gtr:outcomeId><gtr:partnerContribution>To obtain a higher quality of gold coating for the device (essential for its intended function), Nick Oliver's team used the conformal sputtering machine at University of Surrey.</gtr:partnerContribution><gtr:piContribution>Develop and clinically assess a novel continuous glucose monitor (CGM) that overcomes challenges facing commercially available CGM technology by providing an accurate, painless minimally invasive device.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cellnovo</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Herrero-Vi&amp;ntilde;as - P47176 - C</gtr:description><gtr:id>D1030E58-B2BA-4933-9886-A3EC9AFF4F3E</gtr:id><gtr:impact>Dr Herrero-Vinas' team are looking at incorporating ABC4D application into the Cellnovo handheld unit, which already communicates to their insulin pump.</gtr:impact><gtr:outcomeId>545a534db9fe01.66912646-1</gtr:outcomeId><gtr:partnerContribution>Cellnovo (pump manufacturer) is interested in incorporating Dr Herrero-Vinas' software solution (ABC4D) in their products. Dr Herrero-Vinas' team are currently working on such integration.</gtr:partnerContribution><gtr:piContribution>Cellnovo (pump manufacturer) is interested in incorporating Dr Herrero-Vinas' software solution (ABC4D) in their products. Dr Herrero-Vinas' team are currently working on such integration.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biofocus</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Giamas - P47199 - Biofocus</gtr:description><gtr:id>C5AC3DEA-2B2C-4C68-A5C5-5656AE2C4A82</gtr:id><gtr:impact>None stated</gtr:impact><gtr:outcomeId>545b8d64ad0975.05354356-1</gtr:outcomeId><gtr:partnerContribution>Biofocus performed the screening and analysed the data.</gtr:partnerContribution><gtr:piContribution>Giamas' team provided Biofocus with the protein to do the assay/screening.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Domainex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Wigneshweraraj - P47143 - D</gtr:description><gtr:id>497B157D-3C32-46B2-B618-5EB570D925FC</gtr:id><gtr:impact>We are currently preparing a preliminary application for a Wellcome Trust SDDI scheme. Awaiting decision from a BBSRC grant application.</gtr:impact><gtr:outcomeId>545a6409840084.76008441-1</gtr:outcomeId><gtr:partnerContribution>Prof. Wigneshweraraj's team screened the efficiency of libraries of small molecules identified by Domainex scientists to inhibit the enzymatic activity of the bacterial RNA polymerase and growth of Escherichia coli.</gtr:partnerContribution><gtr:piContribution>Prof. Wigneshweraraj's team screened the efficiency of libraries of small molecules identified by Domainex scientists to inhibit the enzymatic activity of the bacterial RNA polymerase and growth of Escherichia coli.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dexcom</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Herrero-Vinas - P47176 - D</gtr:description><gtr:id>B70EAFE4-4B68-4163-9725-65A1276C92DD</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>545a545966d552.52947295-1</gtr:outcomeId><gtr:partnerContribution>Dexcom has provided Dr Herrero-Vinas' team with two investigational devices. The team's main aim is to promote their product among the scientific community since bigger stakeholders such as Medtronic currently dominate the market. Therefore, by acknowledging them in the publications and conferences, the team are benefiting them by publicizing their product.</gtr:partnerContribution><gtr:piContribution>Dexcom has provided Dr Herrero-Vinas' team with two investigational devices. The team's main aim is to promote their product among the scientific community since bigger stakeholders such as Medtronic currently dominate the market. Therefore, by acknowledging them in the publications and conferences, the team are benefiting them by publicizing their product.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Muhimbili University of Health and Allied Sciences</gtr:collaboratingOrganisation><gtr:country>Tanzania, United Republic of</gtr:country><gtr:department>Department of Haematology and Blood Transfusion</gtr:department><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>80B2D850-26CE-4B71-931E-E9333BF0843A</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-7</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Quinlan - DrND</gtr:description><gtr:id>ED65495D-8A5E-4A7E-8C46-B026114F4C8A</gtr:id><gtr:impact>Multidisciplinary; within Imperial involving Medicine and Chemistry and from UCL hepatology. Functioning prototype produced</gtr:impact><gtr:outcomeId>54537f8d110e23.39482997-1</gtr:outcomeId><gtr:partnerContribution>UCL will test this (filter prototype) in an in vivo model of haemolysis.</gtr:partnerContribution><gtr:piContribution>At Imperial we have produced a functioning a filter prototype.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>E1251BC2-F95D-4500-9072-021317C74271</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-13</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Griesenbach - ICiC1 - Prof Amit Nathwani</gtr:description><gtr:id>2D265602-3E08-4C90-93C2-CC1C09EDCBE4</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>58c27f89f14496.26352968-1</gtr:outcomeId><gtr:partnerContribution>Expertise in the relevant disease area and access to patients should a clinical trial be initiated.</gtr:partnerContribution><gtr:piContribution>Expertise in pulmonary gene transfer and the generation of suitable vectors.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Medicine</gtr:department><gtr:description>Snelgrove - ICiC1 - PIP &amp;amp; DMB</gtr:description><gtr:id>E6856ECB-A75D-42EB-8DDA-93E2D8CE1AEA</gtr:id><gtr:impact>Studies formed part of an unsuccessful application to the Wellcome Trust seeding drug discovery scheme and will form part of an application to the MRC DPFS scheme.</gtr:impact><gtr:outcomeId>56cc505baa1254.99954677-1</gtr:outcomeId><gtr:partnerContribution>Provision of clinical samples.</gtr:partnerContribution><gtr:piContribution>Measurement of Leukotriene B4 (LTB4) and PGP in clinical samples via mass spectrometry.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Research Complex at Harwell</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Protein Production Facility-UK (OPPF-UK)</gtr:department><gtr:description>Giamas - P47199 - OPPF</gtr:description><gtr:id>B6847886-69DA-4910-A1D4-4E15D988B0BD</gtr:id><gtr:impact>Dr Giamas' team managed to generate more pure and conformationally accurate LMTK3 protein that has been tested positive for kinase activity in in vitro kinase assays.</gtr:impact><gtr:outcomeId>544fc2a28c3279.32596931-1</gtr:outcomeId><gtr:partnerContribution>As part of this work and in collaboration with OPPF (Oxford Protein Production Facility) Dr Giamas' team have generated additional LMTK3 constructs encompassing the kinase domain that were expressed in various systems (E. Coli, insect cells, etc). OPPF produced the proteins for use in these experiments.</gtr:partnerContribution><gtr:piContribution>As part of this work and in collaboration with OPPF (Oxford Protein Production Facility) Dr Giamas' team have generated additional LMTK3 constructs encompassing the kinase domain that were expressed in various systems (E. Coli, insect cells, etc).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>West African College of Physicians</gtr:collaboratingOrganisation><gtr:country>Nigeria, Federal Republic of</gtr:country><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>8C247C5B-68BA-4A31-AC29-4D55FF3802C5</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-1</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Domainex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Schneider - PS2145 - Domainex</gtr:description><gtr:id>6D86E588-708F-465B-86B9-ACBAFC8CAD41</gtr:id><gtr:impact>This is a multi-disciplinary collaboration, including cell biology, functional genomics, and molecular physiology.</gtr:impact><gtr:outcomeId>54579b3de08425.99871766-1</gtr:outcomeId><gtr:partnerContribution>We have collaborated with Cambridge drug discovery firm Domainex since mid-2013 for molecular modelling, medicinal chemistry, and strategic advice. In addition, the cell-free assays have been performed by Dr Chapman there.</gtr:partnerContribution><gtr:piContribution>The Schneider laboratory has been responsible for the cell biology, functional genomics, and molecular physiology: namely, the development and implementation of cardioprotection assays in human pluripotent stem cell-derived cardiomyocytes, the RNA interference results validating MAP4K4 as a druggable target in the human context, and demonstrating the effectiveness of our best compound in this system.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Thies Medical School</gtr:collaboratingOrganisation><gtr:country>Senegal, Republic of</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>6B3D4DDD-D811-44D9-A278-2D70A8D6700D</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-6</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Long - P46365 - Uni of Manchester</gtr:description><gtr:id>CA0A5A2E-A441-429C-998E-6271C74F7676</gtr:id><gtr:impact>This project has strengthening the link between Professor Allen and Professor Long's group, and further between Manchester University and Imperial College.</gtr:impact><gtr:outcomeId>54520ef61b3652.57449225-1</gtr:outcomeId><gtr:partnerContribution>Prof Allen tested the compound in his in vivo stroke model and then performed MRI</gtr:partnerContribution><gtr:piContribution>We made the compound that Professor Allen then tested in a stroke model, coupled with magnetic resonance imaging (MRI)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Agency for Research on Cancer (IARC)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Virology Department</gtr:department><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>B091F8CD-CA09-4271-8F41-134DE5BD8FC6</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-5</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Edwards, M - P47173 - Pfizer</gtr:description><gtr:id>3F8EF7F0-E459-4821-9467-98E5C11A2F4F</gtr:id><gtr:impact>Have identified new macrolides with Pfizer, still awaiting outcomes. The collaboration is multi-disciplinary; cell biology, immunology, drug discovery and chemistry are the various disciplines involved.</gtr:impact><gtr:outcomeId>544faec08dfe07.09636589-1</gtr:outcomeId><gtr:partnerContribution>Pfizer USA - small library of macrolides provided for screening.</gtr:partnerContribution><gtr:piContribution>Edwards team identified several new that increased virus-induced IFN induction by 200-250% and decreased pro-inflammatory cytokine induction by 60-80% from the small library of macrolides provided for screening by Pfizer.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cyprotex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Stronach - P47197 - Cyprotex</gtr:description><gtr:id>89894371-4538-41A6-A230-F2CCEBFF0D49</gtr:id><gtr:impact>Nothing stated</gtr:impact><gtr:outcomeId>545a11caae9fe4.54727234-1</gtr:outcomeId><gtr:partnerContribution>The interaction with Cyprotex was purely fee for service for kinome screen and ADMET assays respectively.</gtr:partnerContribution><gtr:piContribution>The interaction with Cyprotex was purely fee for service for kinome screen and ADMET assays respectively.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academy of Sciences of the Republic of Tajikistan</gtr:collaboratingOrganisation><gtr:country>Tajikistan, Republic of</gtr:country><gtr:department>Institute of Gastroenterology</gtr:department><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>9D24A291-01E2-46E9-9A55-21C469330E77</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-12</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Bioengineering</gtr:department><gtr:description>ICiC Quantum Dot Biosensor System</gtr:description><gtr:id>358492E2-877F-4BEA-9358-1C3CDB9F7F3F</gtr:id><gtr:impact>None so far, project only commenced September 2013. Outputs expected by the next reporting period (October 2014). 
The work is multi-disciplinary involving bionanotechnology (specifically harnessing the unique properties of nanomaterials in biosensors that should enable highly sensitive and rapid detection of clinically relevant biomarkers) and the collaborators are clinicians working in The Royal Brompton Hospital, researching in cardiac related areas.</gtr:impact><gtr:outcomeId>cJYu4pmMeqw-1</gtr:outcomeId><gtr:partnerContribution>The investigators at NHLI are providing clinical samples for the assay development.</gtr:partnerContribution><gtr:piContribution>For this ICiC project the bioengineers are developing nanoparticle-based assay for the detection of miRNAs, which will be derived from clinical samples provided by the NHLI collaborators. The Confidence in Concept grant made this collaboration possible.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Edinburgh bioQuarter</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Stronach - P47197 - Edinburgh Bioquarter</gtr:description><gtr:id>6B10DCAA-E0E6-4DBB-B8E1-D34127D7D48A</gtr:id><gtr:impact>n/a as this is still on-going</gtr:impact><gtr:outcomeId>545a0e256f4d39.03179896-1</gtr:outcomeId><gtr:partnerContribution>The Edinburgh BioQuarter collaboration began with this project in 2013. BioQ provided important validation of compound phenotype effects in an independent lab. They also carried out detailed time course proteomics and identified pharmacodynamic biomarkers of compound activity. The data produced collectively is being compiled into a patent application for the key structures produced within this project. This is in progress.</gtr:partnerContribution><gtr:piContribution>None stated</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Cancer Institute</gtr:department><gtr:description>Griesenbach - P47167 - ProfAN</gtr:description><gtr:id>70B03CF7-6DAF-48A8-9678-5FDDC5B6663A</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>5450caef53da15.88366073-1</gtr:outcomeId><gtr:partnerContribution>Collaboration with Prof A Nathwani to ensure smooth progression of Professor Grisenbach's gene transfer strategies into clinic, once efficacy in pre-clinical models has been determined</gtr:partnerContribution><gtr:piContribution>Collaboration with Prof A Nathwani to ensure smooth progression of Professor Grisenbach's gene transfer strategies into clinic, once efficacy in pre-clinical models has been determined</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Alabama at Birmingham</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Snelgrove - ICiC1 - DAG</gtr:description><gtr:id>320D2A50-4AA1-4992-B1E8-CC08C7615114</gtr:id><gtr:impact>No impact so far, collaboration and work still on-going.</gtr:impact><gtr:outcomeId>56cc5220dd3712.57721199-1</gtr:outcomeId><gtr:partnerContribution>Provision of specific mouse strains and expertise in murine models.
Provision of clinical samples.
Some downstream analysis.</gtr:partnerContribution><gtr:piContribution>Provision and testing of our novel Leukotriene A4 hydrolase (LTA4H) modulators in murine models and clinical samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dundee Model Railway Club</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Stronach - P47197 - Dundee MRC</gtr:description><gtr:id>4A3096DF-1FA8-48F8-A7C9-44AF95CAF29D</gtr:id><gtr:impact>We have commissioned the Dundee MRC Unit to run kinase profiling on 4 compounds. This is underway and we await data return. This will give us key information on how clear or otherwise the compounds are.</gtr:impact><gtr:outcomeId>545a0fceaf7889.64969731-1</gtr:outcomeId><gtr:partnerContribution>The interaction with Dundee MRC unit was purely fee for service for kinome screen and ADMET assays respectively</gtr:partnerContribution><gtr:piContribution>The interaction with Dundee MRC unit was purely fee for service for kinome screen and ADMET assays respectively</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Heart &amp; Lung Institute (NHLI)</gtr:department><gtr:description>ICiC Quantum Dot Biosensor System</gtr:description><gtr:id>9CC2DE47-1686-4B8C-9301-99B09B239F49</gtr:id><gtr:impact>None so far, project only commenced September 2013. Outputs expected by the next reporting period (October 2014). 
The work is multi-disciplinary involving bionanotechnology (specifically harnessing the unique properties of nanomaterials in biosensors that should enable highly sensitive and rapid detection of clinically relevant biomarkers) and the collaborators are clinicians working in The Royal Brompton Hospital, researching in cardiac related areas.</gtr:impact><gtr:outcomeId>cJYu4pmMeqw-2</gtr:outcomeId><gtr:partnerContribution>The investigators at NHLI are providing clinical samples for the assay development.</gtr:partnerContribution><gtr:piContribution>For this ICiC project the bioengineers are developing nanoparticle-based assay for the detection of miRNAs, which will be derived from clinical samples provided by the NHLI collaborators. The Confidence in Concept grant made this collaboration possible.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Baylor College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Centre for Cell and Gene Therapy</gtr:department><gtr:description>Griesenbach - P47167 - UKCFGTC</gtr:description><gtr:id>CEF87787-E963-4A6A-9734-234561C699F2</gtr:id><gtr:impact>The Consortium is now the world's largest gene therapy group focused on a single disease, with a combined staff of over 50. Professor Griesenback's team of clinical trial programme is well underway.
Medicor awarded &amp;pound;200,000 to the whole of the GTC for the continuation of Consortium CF Gene Therapy work. The award was made on 20/12/13.</gtr:impact><gtr:outcomeId>5450c98cea2f03.49269519-1</gtr:outcomeId><gtr:partnerContribution>All work performed within the UK CF Gene Therapy Consortium is performed in a collaborative fashion across the three sites. The relative contributions of each site are project specific. For the project in question viral vectors were produced by the Oxford arm of the consortium.</gtr:partnerContribution><gtr:piContribution>All work performed within the UK CF Gene Therapy Consortium is performed in a collaborative fashion across the three sites. The relative contributions of each site are project specific. For the project in question efficacy testing of viral vectors was performed by the Imperial team.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Heart &amp; Lung Institute (NHLI)</gtr:department><gtr:description>Snelgrove - ICiC1+2 - ProfCL</gtr:description><gtr:id>C4329616-2786-4A30-806D-9049C5284FDF</gtr:id><gtr:impact>Successful application for an Asthma UK Innovations award. 
Studies also formed part of an unsuccessful application to the Wellcome Trust seeding drug discovery scheme and will form part of an application to the MRC DPFS scheme.
These studies are the subject of a manuscript currently being finalized.</gtr:impact><gtr:outcomeId>56d82b11b81c66.01049859-1</gtr:outcomeId><gtr:partnerContribution>Professor Lloyd is a world leader in murine models of allergic airways disease. She has provided expertise and knowledge of the models and her group have provided technical assistance.</gtr:partnerContribution><gtr:piContribution>We have utilised Professor Lloyd's models of allergic airways disease to test our LTA4H knock-out mice and LTA4H modulators. We conducted all experiments and analysis with some technical help from Professor Lloyd's group,</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Le Dantec Hospital</gtr:collaboratingOrganisation><gtr:country>Senegal, Republic of</gtr:country><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>04A106DE-9511-4356-9E62-E016A298B177</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-4</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dexcom</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Herrero - ICiC1 - Dexcom, Inc, San Diego, USA</gtr:description><gtr:id>781E6789-C28D-4047-843E-1E27BA87071F</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>58c96d532e4fb5.29820003-1</gtr:outcomeId><gtr:partnerContribution>Financial support and providing some feedback regarding the usability of the app.</gtr:partnerContribution><gtr:piContribution>Development of the ABC4D app iOS and backend software (Matlab and webserver) to perform the clinical trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Victoria Teaching Hospital</gtr:collaboratingOrganisation><gtr:country>Gambia, Republic of the</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>D6CD5732-DAB1-4E6A-AE75-A575CDCDF364</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-11</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Jos</gtr:collaboratingOrganisation><gtr:country>Nigeria, Federal Republic of</gtr:country><gtr:department>Department of Gastroenterology</gtr:department><gtr:description>West African Liver Cancer Network</gtr:description><gtr:id>B256B5DD-0687-4383-BDFA-46C7909DA91A</gtr:id><gtr:impact>Invitations to multiple international conferences to present results (see awards &amp;amp; recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.</gtr:impact><gtr:outcomeId>pFZUb1YkQR4-3</gtr:outcomeId><gtr:partnerContribution>Provision of clinical material and clinical expertise in West Africa and Central Asia</gtr:partnerContribution><gtr:piContribution>Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Griesenbach - Imperial Festival</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>22053C13-79E2-4FB6-9BC7-8D234DC88DF1</gtr:id><gtr:impact>Approximately 12,000 people attended Imperial Festival over 3 days.

Sharing information and improving public understanding of research</gtr:impact><gtr:outcomeId>54637120229696.14034949</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www3.imperial.ac.uk/festival</gtr:url><gtr:year>2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Simonds ICiC - European Respiratory Society (ERS) Summer School</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1E428B22-11C4-4D8C-8FAC-909A6AC495E8</gtr:id><gtr:impact>80 doctors attended but presentations were disseminated on ERS website

Small group discussions on 02 therapy</gtr:impact><gtr:outcomeId>5460c97794adc9.50911643</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ersnet.org/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stevens - ICiC1 - Kavli Nanoscience Symposium, Tondheim</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>86F611E8-ABB4-4765-8E32-5612D2B59557</gtr:id><gtr:impact>The Kavli Prizes are awarded biannually in Oslo within the fields of Nanoscience, Neuroscience and Astrophysics.</gtr:impact><gtr:outcomeId>56cb4428953a36.41785316</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.ntnu.edu/physics/kavlis14</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Griesenbach - P47167 - STEML</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>087EB5B3-272F-42EB-864E-538F88BB7C81</gtr:id><gtr:impact>The event aims to provide an insight on current popular research areas in different subject fields, and also gives students a chance to explore university life from a different prospective. 


Several students requested to visit the laboratory to gain relevant experience before applying to university</gtr:impact><gtr:outcomeId>5452698dbbbae7.39433899</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/administration/outreach/eventssummary/event_29-9-2014-15-4-9</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stevens - ICiC1 - Dara O'Brien's Science Club</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4BD546A5-A7EF-42BD-A689-E145F11E9B7E</gtr:id><gtr:impact>Invited as a guest expert</gtr:impact><gtr:outcomeId>56d9703b724dd1.81199438</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b037mkj3</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stevens - ICiC1 - APS Pharm Sci</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>471C8555-23F4-447C-92B2-92DD37E08E6B</gtr:id><gtr:impact>The Academy of Pharmaceutical Sciences held their annual PharmSci Conference at the University of Hertfordshire de Havilland campus, from 8th -10th September 2014. PharmSci 2014 addressed 'Working together for patients'. The conference attracted nearly 600 participants from academia, industry and regulatory authorities over the 3 days.

The conference also provided many networking opportunities and an enjoyable social side with a lively debate on the Monday evening, 'The role of universities in open innovation research: academic entrepreneurship or industrial exploitation?' and on the Tuesday evening the APS annual &amp;quot;Black Tie&amp;quot; Dinner at Knebworth House with an inspirational talk from Elin Haf Davies</gtr:impact><gtr:outcomeId>56cb453c5d0852.96035236</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ukpharmsci.org/2014resourcepack/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edwards, M - American Thoracic Society, San Francisco</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AA5FAAB3-1B65-41D9-A879-F1C3633C4DF1</gtr:id><gtr:impact>Azithromycin Augments RV-Induced Type I &amp;amp; III IFN Production Via Interaction with MAVS Michael R. Edwards, James D. Porter, Musa Khaitov, Sergei Moshkovski , Lyn Jones, Lee Roberts, Kalesh K.N. Anandamma, Iain Kilty, Ed Tate, Sebastian L. Johnston. Oral Presentation, American Thoracic Society, San Francisco, USA 2016. 

A talk of 15 minutes, and discussion for 5-7 mins including questions from the audience. Outcome was to disseminate information regarding science and asthma treatments. Outcome or impact is unknown.</gtr:impact><gtr:outcomeId>58a4434e0b7cf5.35637899</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.atsjournals.org/doi/abs/10.1164/ajrccmconference.2016.193.1_MeetingAbstracts.A6421</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Long - P46365 - Dalton Discussion meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>51F25A29-DFAE-4FCD-94C3-0FDC0ADA8001</gtr:id><gtr:impact>There were presentations of research work, followed by extended question and answer sessions, where research issues were aired and talked through. This will affect future research and help to guide others research. There were further discussions during the lunch and evening sessions and the papers will be collected within a special issue of Dalton Transactions in February 2015.

As above, a special issue of the main UK inorganic chemistry journal will be the results of the meeting.</gtr:impact><gtr:outcomeId>54521bd84a0290.65443411</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www.rsc.org/ConferencesAndEvents/RSCConferences/DD15/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Long - P46365 - DrGS - EU COST (EUFEN3) action meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>02FB927C-F75E-4B51-9843-44758193A1AB</gtr:id><gtr:impact>Research presentation to colleagues in the f-element field. Good discussion on specific and wider aspects of f-element chemistry

Good discussion on specific and wider aspects of f-element chemistry</gtr:impact><gtr:outcomeId>5452172b4635b6.17612966</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.nottingham.ac.uk/~pczstl/CM1006/EUFEN3.htm</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>JDRF Discovery Evening</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3743D4BA-72A1-48BB-BE3B-A381F14BD61C</gtr:id><gtr:impact>Members of the ICiC project on Advanced Bolus Calculator for Diabetes presented their work at this event. This was an opportunity for adults living with type 1 diabetes to meet others with the condition and learn about the latest Juvenile Diabetes Research Foundation research. The event also included inspirational talks from adults living and working with Type 1 diabetes

Event occurred on 13th November 2013, no impact so far</gtr:impact><gtr:outcomeId>ofsYxQVE5Dt</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.jdrf.org.uk/research/research-events/type-1-discovery-evening</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edwards - XVI International Symposium on Respiratory Viral Infections Seoul, Korea 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DC33B868-B4C5-473D-94E5-8C74EA924593</gtr:id><gtr:impact>Presented a seminar at a virology conference (RVI) the audience were approx several hundred, the abstract would reach several thousand.

N/A</gtr:impact><gtr:outcomeId>5463380e1dadc7.26728741</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www.themacraefoundation.org/wp-content/uploads/2013/08/Final-Program-2.pdf</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Griesenbach - P47167 - Heart and Lung Repair Shop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>468571F1-331A-4096-BD4F-6803ACBD5C58</gtr:id><gtr:impact>The audience were asked to vote on The Heart and Lung Repair Future Challenges. The winning challenge, receiving 699 votes, was 'Repair Your Own Organs' which was a challenge to develop drugs to stimulate the body's own stem cells to heal itself. The other challenges were 'Build a Heart' receiving 184 votes, 'Make Cigarettes Healthy' receiving 278 votes and 'Better Treatment for Lung Cancer' receiving 408 votes; special events were held including debates about the future of heart and lung repair, facilitated by Y Touring Theatre Company and a debate workshop with students from Hammersmith Academy.

2750 people visited The Heart and Lung Repair Shop during the two weeks it was open.</gtr:impact><gtr:outcomeId>5452614fc03fe0.96044509</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www1.imperial.ac.uk/nhli/public_engagement/the_curious_act/heart_and_lung_repair_shops/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stevens - ICiC1 - NPL Workshop: Nanoparticle concentration, chemistry and interfaces</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0352F1D9-013B-4026-ABB4-D48260368C1D</gtr:id><gtr:impact>Workshop: Nanoparticle concentration, chemistry and interfaces. This four-day workshop will engage international experts in a lively scientific debate around the measurement of concentration of nanoparticle in media, their chemistry and the nature of critical interfaces. It was attended by member(s) of Prof Stevens group.</gtr:impact><gtr:outcomeId>56cb36c439c5d8.92872813</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.npl.co.uk/np-workshop/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Long/Gavins - P46365 - Pharmacology 2014, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5F08E536-D757-46F0-96DF-915B0DEECDEC</gtr:id><gtr:impact>Poster presentation given at pharmacology 2014 conference London. We hope the presentation will reach a wide audience and initiate conversations and debate about the work and future directions.

n/a</gtr:impact><gtr:outcomeId>5452191d995138.09905905</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.bps.ac.uk/meetings/Pharmacology2014</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Griesenbach - P47167 - Rare Disease Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9680831F-3F53-45FB-A1CB-D8FBDE69FBCD</gtr:id><gtr:impact>Since Rare Disease Day was first launched by EURORDIS and its Council of National Alliances in 2008, more than 1000 events have taken place throughout the world reaching hundreds of thousands of people and resulting in a great deal of media coverage.

Even though the campaign started as a European event, it has progressively become a world event, with a record-breaking 84 countries participating in 2014. IRRD hope many more will join in 2015. IRRD's objective is for the WHO to recognise the last day of February as the official Rare Disease Day and to raise increasing awareness for Rare Diseases worldwide.</gtr:impact><gtr:outcomeId>5452632b93bfe3.14570287</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.rarediseaseday.org/article/what-is-rare-disease-day</gtr:url><gtr:year>2008,2010,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stevens - ICiC1 - Corday Morgan Lecture (Award)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>98E03140-852C-4837-B228-4F2B0E17E92E</gtr:id><gtr:impact>The Corday-Morgan Prizes are awarded for the most meritorious contributions to chemistry. It runs annually, there are up to three prizes available, winners receive &amp;pound;5000, a medal and a certificate, to be presented at the Prize ceremony in November, the winners will undertake UK lecture tours and prize winners are chosen by the RSC Awards Working Group. Prof Molly Stevens was the winner of this prize in 2014</gtr:impact><gtr:outcomeId>56cb3d120ba1f7.26936947</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.rsc.org/events/detail/17280/2014-corday-morgan-prize-winner-lecture</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oliver ICiC - The microprobe sensor advisory group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2D9193A6-E02A-4FE1-A8C8-E26C9790F5D1</gtr:id><gtr:impact>The group is formed of 8 members and meets on regular interval to discuss update and plans for the following phase of the project.

It allowed the group to view the project from patients' perspective and to modify the protocol accordingly. As mentioned, the group participated in protocol and in developing participant information material. The PPI at an early stage of this project was positively viewed by reviewers of the NIHR i4i grant (awarded on June 2013).</gtr:impact><gtr:outcomeId>54536dc06568d1.32550808</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Shamji ICiC -American Academy of Allergy, Asthma and Immunology annual meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>554D79C3-68BA-450A-86F7-D5F8D407F906</gtr:id><gtr:impact>American Academy of Allergy, Asthma and Immunology (AAAAI) annual meeting in San Diego, USA.
The AAAAI featured poster session was well attended and a 5-10 minute presentations was given on the research, which was then followed by question and answer session. The session was attended by 50-100 delegates.


N/A</gtr:impact><gtr:outcomeId>545ba18d85d0b9.68234139</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://annualmeeting.aaaai.org/</gtr:url><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stevens - ICiC1 - Nanotechnology &amp; Medicines for Tomorrow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9919BB9C-84BA-450B-9691-CA0DF4E54374</gtr:id><gtr:impact>Biomedical Research Victoria (BioMedVic) is the peak body for the organisations that make up this internationally-recognised research community, providing a collective voice for advocacy and a structure for promoting collaboration and innovation.

Representing universities, teaching hospitals, medical research institutes, CSIRO and other research organisations, Biomedical Research Victoria seeks to develop shared vision, long term plans and better links between government, industry and the biomedical community.

Prof Stevens was the plenary speaker at the November 2014 meeting</gtr:impact><gtr:outcomeId>56cb41c8495cd3.24662609</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://biomedvic.org.au/symposium/nanotechnology-and-medicines-for-tomorrow/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wigneshweraraj - ICiC1 - RNA Polymerase Workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>68028AF4-F6BE-40E4-AA8E-3999F6112B32</gtr:id><gtr:impact>The Annual RNA Polymerase Workshop, hosted by David Grainger and David Lee, came to the University of Birmingham last week. The workshop ran over two days and featured 22 talks across four sessions. The overall focus of the meeting was the mechanism and regulation of transcription.</gtr:impact><gtr:outcomeId>56cc3bada3f024.59176972</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://imibirmingham.com/2015/05/13/an-overview-of-the-27th-uk-rna-polymerase-workshop-2/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gavins - Experimental Biology 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4A826CBB-AF51-489F-A92C-5FAFACB41BCD</gtr:id><gtr:impact>Research presentation to colleagues biology and imaging fields. Good discussion on specific and wider aspects of f-element chemistry

N/A</gtr:impact><gtr:outcomeId>54638194a05934.19757208</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://experimentalbiology.org/2014/Home.aspx</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Herrero - ICiC1 - Astra-Zeneka sponsored event in Madrid</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6B9AD72B-0E6C-4199-A0CF-354033DCC841</gtr:id><gtr:impact>More than 100 endocrinologists and around 15 from around Spain from Astra-Zeneka attended the talk (1 hour) about the ABC4D system which sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58c966226d2050.43851241</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stevens - ICiC1 - Fourth International Conference on Multifunctional, Hybrid and Nanomaterials</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4C5CF0A6-A011-4687-A0E6-CE6F99E76FD2</gtr:id><gtr:impact>The main objective of this large interdisciplinary conference is to bring together, at a truly international level, people with shared interests in hybrid materials. Prof Stevens was a featured speaker.</gtr:impact><gtr:outcomeId>56cb3e7d281be8.69263648</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.materialstoday.com/polymers-soft-materials/events/hybrid-materials-2015-/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Shamji - British Society of Allergy and Immunology meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B1E1B15F-A8F3-409B-9BA6-57D4E51EB80F</gtr:id><gtr:impact>British Society of Allergy and Immunology (BSACI) meeting, Telford, UK

Research findings were presented at the BSACI meeting. The symposium was attended by 50-100 delegates. Questions and Answer session was followed after the presentation


N/A</gtr:impact><gtr:outcomeId>545c94d7e2e249.94171171</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.bsaci.org/announcements/bsaci-annual-meeting-2014</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Giamas - P47199 - 9th International Conference of Anticancer Research 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>537FA66E-6CDB-4BBA-8DFE-432072A516F6</gtr:id><gtr:impact>Approximately 50 scientists attended the talk, followed by questions and discussion.

Potential future collaborations with other groups were discussed.</gtr:impact><gtr:outcomeId>545b8eb3467438.86271920</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.iiar-anticancer.org/conference/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Taylor-Robinson - ICiC1 - AMMF</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>399F4108-E8FF-4997-8E1F-2AA4BC5591DB</gtr:id><gtr:impact>AMMF held a research update event at Imperial College in Feb 2015. 200 members of the public attended an open day at Imperial College London with a series of lectures on our research and the opportunities to ask questions in a &amp;quot;Question Time&amp;quot; debate</gtr:impact><gtr:outcomeId>56cadf67e80cc1.10716239</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.ammf.org.uk/2015/03/16/ammf-at-imperial-college-11-03-15/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Griesenbach - P47167 - In2SUK</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9BC2416A-CDD9-495E-B4DF-0CC66C4BC27E</gtr:id><gtr:impact>In2science scheme works to leverage the commitment, passion and experience of scientists to ensure the brightest pupils have the opportunity to experience research science first hand, regardless of their wealth. Students work alongside practising scientists for a 2 week placement during the summer, giving students an insight into scientific research.

Placements will be highly valued by future employers and admissions tutors at centres of higher education and will enable scientists to inspire the next generation. Several students requested to visit the laboratory to gain relevant experience before applying to university</gtr:impact><gtr:outcomeId>5452649bf36a93.54646955</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://in2scienceuk.org/scientist.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Griesenbach - ICiC1 - Rare Disease Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>24F2E649-BD56-4E58-98FB-C8DA3C80A957</gtr:id><gtr:impact>Raising awareness for genetic diseases.</gtr:impact><gtr:outcomeId>58c28463f02c27.39183798</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edwards - P47173 - American Thoracic Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FEE9E080-0F55-491C-B6D2-EC1359A11BF7</gtr:id><gtr:impact>Presented a poster at at poster discussion session (ATS) the audience were approx several hundred, the abstract would reach several thousand.

Novel inhibitors of TGF-beta activating kinase (TAK1) uncouple beneficial anti-viral innate immunity from harmful virus-induced pro-inflammatory responses in models of rhinovirus infection. Michael R. Edwards, Katie Chapman, Jennifer J. Haas, Louise Slater, Albert Jaxa-Chamiec, Caroline Low, Hayley Cordingley, Roberto Solari, Sebastian L. Johnston Catherine Tralau-Stewart. Poster Presentation, American Thoracic Society, San Diego, USA 2014.

N/A</gtr:impact><gtr:outcomeId>5453c5a951fe23.96473128</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.thoracic.org/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stevens - PS2142_MMRE - MRSUS</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D874817B-2C3D-475A-83C7-0F0681D9954D</gtr:id><gtr:impact>Over 6000 attended the 2014 MRS Spring Meeting, thus making it hugely successful. The presentations and discussions of materials science and their impact in healthcare applications were very exciting and spurred numerous collaborations and new projects. Prof Stevens was interviewed by MRS TV to discuss the exciting scientific talks and atmosphere present at the meeting, where several Stevens Group members also presented their work.

The MRS Meetings are an excellent source for materials-based research scientists to present their latest results and network with peers to strengthen their research directions and possibilities. This Spring Meeting was an incredible display of the level of research currently ongoing in our fields</gtr:impact><gtr:outcomeId>545900dc2f0e96.45848516</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www.mrs.org/spring2014/</gtr:url><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Brompton &amp;amp; Harefield NHS Foundation Trust Seed Funding</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:fundingOrg><gtr:id>EB805228-840E-4E0A-9B8D-CD2E70737620</gtr:id><gtr:outcomeId>56cc6d64b68a26.23781033</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Breast Cancer Campaign small pilot grant</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Breast Cancer Campaign (BCC)</gtr:fundingOrg><gtr:fundingRef>2013MaySP004</gtr:fundingRef><gtr:id>0742C612-D941-469E-AA93-977CD039FEC6</gtr:id><gtr:outcomeId>544fc3d4308c00.09379063</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Programme Grant</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C37/A18784</gtr:fundingRef><gtr:id>04B0B1EF-1EC3-4D04-91A5-93789E0A8541</gtr:id><gtr:outcomeId>56d84723add2d3.39884170</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept 4</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>73009D50-5DC3-4AE3-881C-232E3B053ED5</gtr:id><gtr:outcomeId>56e02fe253ee09.13733065</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1218879</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Horizon 2020</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>C3A81237-9FD1-456B-A7D1-31DAEC53C4F7</gtr:id><gtr:outcomeId>56d8539f612ec0.92336947</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>96000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>EPSRC Centres for Doctoral Training</gtr:department><gtr:description>Studentship EPSRC CDT in Neurotechnology for Life and Health</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Imperial College London</gtr:fundingOrg><gtr:id>7EE3B1CF-B21D-4960-A608-3A9F9C467966</gtr:id><gtr:outcomeId>54521187b01e40.03449563</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>46540</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Asthma UK Innovations Award</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:fundingRef>AUK-IG-2014-286</gtr:fundingRef><gtr:id>2B971ECC-76C5-46A1-953B-E514D1DC1854</gtr:id><gtr:outcomeId>5458a511a60759.81683989</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>Liechtenstein, Principality of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medicor funding</gtr:description><gtr:fundingOrg>Medicor Foundation</gtr:fundingOrg><gtr:id>34D571AA-BE19-44A6-BF94-001941F413F0</gtr:id><gtr:outcomeId>54510ed922ca24.44269709</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>191757</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Dexcom Industry Funding</gtr:description><gtr:fundingOrg>Dexcom</gtr:fundingOrg><gtr:id>CBC547B9-1D09-4BF6-993F-C59E52BD5792</gtr:id><gtr:outcomeId>56e03213116d11.43212688</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Unit</gtr:department><gtr:description>NIHR Respiratory Biomedical Research Unit funding for PhD fellows</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:fundingOrg><gtr:id>C8209720-1737-4CAC-8FFA-353C6E568C07</gtr:id><gtr:outcomeId>5457b420910340.36776880</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>718235</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Invention for Innovation (I4I)</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>II-LA-0313-20004</gtr:fundingRef><gtr:id>2BE781E7-9565-4FD7-BB02-1C88DA3C92E5</gtr:id><gtr:outcomeId>54536b4054e163.85484332</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>186887</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Clinical Research Training Fellowship</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>BA4977FF-BF35-4C1D-B3FF-70C96981266E</gtr:id><gtr:outcomeId>56c48d23d89a22.78216823</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Imperial ISSF Sabbatical Award</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>878B08E3-D719-455F-8248-14CAFDEA7B87</gtr:id><gtr:outcomeId>5458df8355b1f4.75521293</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0FB11DE6-9851-4DE9-99B7-C86B6FEB97CA</gtr:id><gtr:outcomeId>5464cae216efc4.03865358</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>191000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Breast Cancer Campaign project grant</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Breast Cancer Campaign (BCC)</gtr:fundingOrg><gtr:fundingRef>2014MayPR234</gtr:fundingRef><gtr:id>263D0B35-1F9A-4946-93C9-31B4B864E543</gtr:id><gtr:outcomeId>544e3632b20082.00587340</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>165000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Respiratory Biomedical Research Unit</gtr:department><gtr:description>Biomedical research unit (BRU) funding</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:fundingOrg><gtr:id>A7D29EF4-EBEC-4FEC-B329-3C2525F7C30B</gtr:id><gtr:outcomeId>56d728c6bfa005.15336489</gtr:outcomeId><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>78000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Action Against Cancer grant</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Action Against Cancer (AAC)</gtr:fundingOrg><gtr:id>0383A050-AB5E-47DA-9139-B79BE7C89749</gtr:id><gtr:outcomeId>5457511b2882b9.69371245</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept 3</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A4C6A7B8-3B4B-4783-B297-EE12AD3A3989</gtr:id><gtr:outcomeId>56e02fab971593.23997609</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Lung Foundation Napp travel fellowship</gtr:description><gtr:fundingOrg>British Lung Foundation (BLF)</gtr:fundingOrg><gtr:id>8BE4D24D-8D2C-450B-854D-77FB2F69DA8C</gtr:id><gtr:outcomeId>56d72936509055.15633479</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>184041</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC i-sense IRC Fellowship</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>A815FBF9-980C-4B59-A781-3122F619C834</gtr:id><gtr:outcomeId>56cb2b04694f06.06242692</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3065</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society of Chemistry Travel Grant</gtr:description><gtr:fundingOrg>Royal Society of Chemistry</gtr:fundingOrg><gtr:id>97E6DD7C-8D99-4F7D-874D-992E20017654</gtr:id><gtr:outcomeId>56d83e12bbdb92.46849166</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16133</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Doverdale Trust Fund</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:fundingOrg><gtr:id>9C20B925-541F-45ED-8437-033224D1030D</gtr:id><gtr:outcomeId>545392c17d8780.74261835</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Seeding Drug Discovery</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>F59D0327-CBB2-4201-A42D-A739C93F973E</gtr:id><gtr:outcomeId>56d06eba74cb73.08395994</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4499155</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Late Stage Seeding Drug Discovery Award</gtr:description><gtr:end>2019-11-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>205256/Z/16/Z</gtr:fundingRef><gtr:id>217D3D0C-F457-44ED-9756-3256415E7AF2</gtr:id><gtr:outcomeId>58beedf442a2a6.74203120</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>201028</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC i-sense IRC Fellowship</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>F35722EC-1A88-4561-87CF-F82D9564ABDD</gtr:id><gtr:outcomeId>56c49667c20985.01552127</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Halley Stewart Fellowship</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Sir Halley Stewart Trust</gtr:fundingOrg><gtr:id>A4847299-26C3-4629-8A70-136B430B1DD4</gtr:id><gtr:outcomeId>56d8408604a940.91980620</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>421836</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Imperial Biomedical Research Centre</gtr:department><gtr:description>NIHR Imperial BRC - BioAID</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>CDF46D4D-9769-4088-B96D-34265D1A1C95</gtr:id><gtr:outcomeId>5458bcfe1e1854.10544928</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Merieux Foundation</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Merieux Foundation</gtr:fundingOrg><gtr:id>20C9F736-F5B8-42D7-95F3-779C0369BA05</gtr:id><gtr:outcomeId>545a185bee2588.56876594</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Egyptian Newton Fund</gtr:description><gtr:fundingOrg>British Council</gtr:fundingOrg><gtr:id>832EBFA6-68A9-4BE2-9E63-320F1F5C8452</gtr:id><gtr:outcomeId>56cae5b1ea1a05.89218589</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>24954</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proof of Concept funding - Imperial Innovations</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Imperial Innovations</gtr:fundingOrg><gtr:id>36E496FC-DD11-48E8-A6B8-44A72BCD607C</gtr:id><gtr:outcomeId>546387097a6375.62945839</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2372000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Portfolio Grant for Alpha 1 antitypsin deficiency and haemophilia</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>EB5B2F71-7231-4C98-8073-65F670254EDE</gtr:id><gtr:outcomeId>58c287e29407d4.09708590</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>193000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Extension Translation Award - A Bio-inspired Artificial Pancreas for Control of Type 1 Diabetes in the Home</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>6A107431-9739-4A66-8A17-F667E57E275D</gtr:id><gtr:outcomeId>58c96acf14c981.09608289</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>LMTK3 as a prognostic marker for breast cancer treatment and to select appropriate therapy</gtr:description><gtr:grantRef>MC_PC_12015</gtr:grantRef><gtr:id>4BF5B9A4-787F-4D93-8C5C-A6F10F918779</gtr:id><gtr:impact>Breast Cancer Campaign small Pilot grant nominated to Dr Georgios Giamas (Ref No: 2013MaySP004). 'Assay development and hit finding against LMTK3'. 1 year grant from 19th August 2013. Total value = &amp;pound;20,000.
Action Against Cancer grant. PI: Prof Justin Stebbing. 'Assay Development and Compounds Screening for LMTK3'. 1st July 2012 to 30th June 2015. Total value = &amp;pound;78,000
9th International Conference of Anticancer Research, 6-10 October 2014, Sithonia, Greece (Oral presentation) 'Positioning LMTK3 on the map of oncogenic signalling cascades and elucidating its role in invasion and metastasis in Breast Cancer'</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>54634db5d1cf67.46450230</gtr:outcomeId><gtr:patentId>US201113639590 20110406</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Methods for categorising cancer such as breast cancer</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The Advanced Bolus Calculator for Diabetes (ABC4D) is a decision support system based on case-based reasoning (CBR). CBR is an artificial intelligence problem solving framework that solves a newly encountered problem (e.g. meal insulin dosing), based on the information obtained from previously solved problems (cases). 
ABC4D is implemented in a smartphone application and utilises continuous glucose monitoring data to provide personalised and adaptive insulin bolus advice. Safety and clinical feasibility of the ABC4D app have been evaluated on 10 type 1 subject over a period of 6 weeks.</gtr:description><gtr:grantRef>MC_PC_12015</gtr:grantRef><gtr:id>35CC1082-C4DE-4E0E-913E-258449FDF22C</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c96867b18ea3.66741958</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Advance Bolus Calculator for Diabetes Management (ABC4D)</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Not stated</gtr:description><gtr:grantRef>MC_PC_12015</gtr:grantRef><gtr:id>60A330E2-AF03-44A4-824E-78488DBAAE5F</gtr:id><gtr:impact>None stated</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>5460f30f5afd76.79157649</gtr:outcomeId><gtr:patentId>WO2014GB51249 20140422</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Urinary Markers of Hepatocellular Carcinoma</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oliver ICiC - JDRF Continuous Glucose Monitoring Roundtable</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>17282707-E79C-46B9-99DB-13E6E506C869</gtr:id><gtr:outcomeId>54537019a1ce56.65609435</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type><gtr:url>https://www.jdrf.org.uk/research/type-1-diabetes-research-roadmap</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Wigneshweraraj - ICiC1 - Berlin</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>1748C930-B552-4D16-B874-439B179A0F83</gtr:id><gtr:impact>Contribution to defining the MRC/BBSRC AMR theme 4 call for applications at a workshop in Berlin.</gtr:impact><gtr:outcomeId>56cdbcb80347a9.04290385</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This study aims to assess the safety and efficacy of a novel advanced bolus calculator in subjects with Type 1 diabetes. Insulin bolus calculators have been developed to aid insulin dose adjustment and existing standard insulin bolus calculator consist of a simple algorithm that requires five subject-specific parameters as input to generate a recommended bolus insulin dose: current blood glucose (mmol/L); target blood glucose (mmol/L); insulin-to-carbohydrate ratio (grams of carbohydrate per 1 unit of insulin); total grams of carbohydrate in meals; insulin sensitivity factor (reduction in glucose per 1 unit of insulin).
The Diabetes Technology team at Imperial College have developed a novel advanced bolus calculator. The complete integrated system consists of a commercially available smartphone that holds the novel advanced algorithm. The system requires regular updates of cases derived from retrospective blinded continuous glucose monitoring data and for this a commercially available glucose sensor will be used. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (blood glucose following a meal). The novel decision support algorithm is based on case-based reasoning (CBR). CBR is an artificial intelligence technique that tries to solve newly encountered problems by applying the solutions learned from solved problems encountered in the past.
The end-product is therefore a subject specific insulin bolus calculator that continues to improve with time. The project utilises commercially available glucose sensors and smartphones (iPhone), integrated with a novel algorithm for insulin bolus calculation. The aim of the ABC4D is to minimise high and low glucose excursions which are associated with the complications of diabetes including blindness, kidney failure, nerve damage and cardiovascular disease.
The clinical study has been designed to incrementally assess the device's ability to manage meal time insulin requirements at breakfast and lunch in a controlled supervised clinical environment over 8 hours (phase 1), followed by its use in the home environment over a 6 week period (phase 2) and finally over a 6 month period (phase 3).
The most recent principle source of funding has been 'Imperial Confidence in Concept Scheme &amp;amp;
Imperial NIHR Biomedical Research Centre /Imperial Innovations Therapeutic primer fund'. 
The clinical trial (phase 2) is currently active with the available funding. We are currently actively seeking for more funding to carry out the next phase of the clinical trial (phase 3).</gtr:description><gtr:id>8882C950-024D-41F7-B4E9-64648E9F207E</gtr:id><gtr:impact>Very positive feedback on usability of the ABC4D system was obtained from a focus group carried out with six volunteers with type 1 diabetes.</gtr:impact><gtr:outcomeId>545a5af4c386d4.61982588</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Herrero-Vi?as - P47176 - ABC4D</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT02053051</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>NIHR Respiratory BRU funding for PhD fellow</gtr:description><gtr:id>C4C04AA7-EAC2-4C51-BC92-AE3AF105FF8F</gtr:id><gtr:impact>Trial ongoing</gtr:impact><gtr:outcomeId>5460eb19556d54.58546644</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Simonds ICiC - Evaluating intelligent oxygen therapy</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The device consists of a patch containing several microscopic projections. When applied to skin surface, these projections painlessly penetrate the outermost skin layer to sense glucose level within the tissues in a continuous manner. It aims at overcoming drawbacks of existing technology particularly by providing painless and more accurate continuous glucose readings. We are currently assessing the device's safety and performance in clinical studies and we are funded by a grant for NIHR I4I scheme.</gtr:description><gtr:id>1399D3E8-13BA-4386-BE33-7EBC9B993A9E</gtr:id><gtr:impact>Potentially, the device could allow a more accurate and significantly cheaper technology for continuous glucose monitoring (CGM), which can subsequently result in wider use of this technology in people with diabetes. CGM was shown to improve control of diabetes with subsequent reduction in complications.</gtr:impact><gtr:outcomeId>5464aa53e85f33.33590911</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Oliver ICiC - Microprobe array continuous glucose monitor</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>http://clinicaltrials.gov/ct2/show/NCT01908530?term=microprobe&amp;rank=1</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We have developed selective small molecule inhibitors of cyclin-dependent kinases, CDK7 and CDK9, which are required for regulation of transcription in metazoans. Cancer features many oncogenes that are transcriptional regulators and targeting transcription would provide a powerful anti-tumour strategy.</gtr:description><gtr:id>E95387F4-52C4-4564-9136-780F6976B182</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>544f6afd528119.34908585</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Coombes - ICEC0942</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>This work is currently funded by Action Against Cancer.</gtr:description><gtr:id>702AD551-B06F-49F5-BEFB-A609C9A0CEB2</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>54634fdde9c947.42339374</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Giamas - LMTK3 inhibitor</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>As part of this project Professor Griesenbach's team generated plasmids suitable for the production of F/HN pseudotyped lentiviral vectors carrying FVIII. Lentiviral vectors have been constructed and assessed for efficacy in relevant models</gtr:description><gtr:id>2334975F-5261-4F2A-B824-FC3580D42D6E</gtr:id><gtr:impact>Presented work related to the novel vector platform at the American Society for Gene Therapy Symposium 2014</gtr:impact><gtr:outcomeId>5450d22e44b081.70822240</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Griesenbach - P47167-plasmids suitable for the production of F/HN pseudotyped lentiviral vectors carrying FVIII</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Developed a novel cell based screening assay involving the activation of two virus-inducible transcription factors; NF-?B, required for over 100 pro-inflammatory cytokines and IRF3; a transcription factor central to IFN gene expression.</gtr:description><gtr:id>BE69CE79-2C22-4790-9638-4CC4C654F638</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>544f7fe68fab59.10814876</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Edwards - P47173</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Potential new inhibitor against a kinase implicated in cancer development.</gtr:description><gtr:id>5B443E81-A6FC-491A-A7FD-0D983DF4AEDA</gtr:id><gtr:impact>None stated at present</gtr:impact><gtr:outcomeId>545b8e2caf01f0.36646381</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Giamas -  LMTK3 inhibitors</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>E-IVIG demonstrated to be a highly purified protective derivative of regular IVIG in vitro and in treatment of invasive group A streptococcal infection. Reagent described in Scientific Reports (Reglinski et al, 2015)</gtr:description><gtr:id>252477ED-912A-44BC-855D-15217DD4DB9F</gtr:id><gtr:impact>Other academic groups have used IVIG as a positive control for development of surrogate of immunity assays for GAS .</gtr:impact><gtr:outcomeId>56dd5a93ea9fc2.52395498</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Srsikandan - ICiC1 - E-VIG</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C81D9939-B162-4619-BB97-20E095EE6CDD</gtr:id><gtr:title>Enhancing automatic closed-loop glucose control in type 1 diabetes with an adaptive meal bolus calculator - in silico evaluation under intra-day variability.</gtr:title><gtr:parentPublicationTitle>Computer methods and programs in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b48195226a83fab0c38e5093a0adfeb9"><gtr:id>b48195226a83fab0c38e5093a0adfeb9</gtr:id><gtr:otherNames>Herrero P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0169-2607</gtr:issn><gtr:outcomeId>5a6ef1c07a82b5.30358300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAF3C6DF-1DFA-4B74-88B8-88514D394628</gtr:id><gtr:title>Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a4699885e78f22938054f1dffd0990b"><gtr:id>3a4699885e78f22938054f1dffd0990b</gtr:id><gtr:otherNames>Ladep NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>544e31914d51e9.74143384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BBAC745-E1AF-4FB5-9C28-EF5BF111B020</gtr:id><gtr:title>Advanced Insulin Bolus Advisor Based on Run-To-Run Control and Case-Based Reasoning.</gtr:title><gtr:parentPublicationTitle>IEEE journal of biomedical and health informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b48195226a83fab0c38e5093a0adfeb9"><gtr:id>b48195226a83fab0c38e5093a0adfeb9</gtr:id><gtr:otherNames>Herrero P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2168-2194</gtr:issn><gtr:outcomeId>545a4ff802b468.31317395</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2289433D-5B4F-41BB-BCEE-A2AFBF8FEF0C</gtr:id><gtr:title>Use of microneedle array devices for continuous glucose monitoring: a review.</gtr:title><gtr:parentPublicationTitle>Diabetes technology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30ea067afd0fc7507e51c16714170ccc"><gtr:id>30ea067afd0fc7507e51c16714170ccc</gtr:id><gtr:otherNames>El-Laboudi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1520-9156</gtr:issn><gtr:outcomeId>54576bad1e3a23.30426070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D582E607-0F78-4177-9ADF-9AAFD93F3DBC</gtr:id><gtr:title>Abstract A47: DNA-PKcs is amplified in high-grade serous ovarian cancer (HGSC), correlates with poor outcome and drives resistance to platinum therapy via the AKT signaling pathway</gtr:title><gtr:parentPublicationTitle>Molecular Cancer Therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cead5da3dfe7cd4c6a498e5b2c4472a"><gtr:id>6cead5da3dfe7cd4c6a498e5b2c4472a</gtr:id><gtr:otherNames>Curry E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d4227d2f2bb7.81361522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65C48570-1200-4E1C-8F8C-F1298B9BBB9D</gtr:id><gtr:title>Case-Based Reasoning for Insulin Bolus Advice.</gtr:title><gtr:parentPublicationTitle>Journal of diabetes science and technology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b5cedac6b7e9555e1ab1e3478dd20e4"><gtr:id>6b5cedac6b7e9555e1ab1e3478dd20e4</gtr:id><gtr:otherNames>Pesl P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-2968</gtr:issn><gtr:outcomeId>5a6f07ef0625b9.96166964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>321621CD-285C-4EFD-A83D-6660E5AF7057</gtr:id><gtr:title>A Critical Role for Monocytes/Macrophages During Intestinal Inflammation-associated Lymphangiogenesis.</gtr:title><gtr:parentPublicationTitle>Inflammatory bowel diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e91a19347f609737dd0d2ef611754828"><gtr:id>e91a19347f609737dd0d2ef611754828</gtr:id><gtr:otherNames>Becker F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-0998</gtr:issn><gtr:outcomeId>58c184428887e9.66970851</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>959FB6B5-75E5-49AC-901C-3CDC33985F30</gtr:id><gtr:title>Identification of the Streptococcus pyogenes surface antigens recognised by pooled human immunoglobulin.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9319a69002ca198f3bdf3dd730d8501"><gtr:id>f9319a69002ca198f3bdf3dd730d8501</gtr:id><gtr:otherNames>Reglinski M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56d9ab0d807279.69024081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8408737-998A-4823-A150-172292327E76</gtr:id><gtr:title>Both MC1 and MC3 Receptors Provide Protection From Cerebral Ischemia-Reperfusion-Induced Neutrophil Recruitment.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7318fc42a1b0e08958f5898ee9c34e1a"><gtr:id>7318fc42a1b0e08958f5898ee9c34e1a</gtr:id><gtr:otherNames>Holloway PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>58c181487c8ba3.96944359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>411B0703-AB33-48B6-9B2C-75CC0912B3E9</gtr:id><gtr:title>Working towards a group A streptococcal vaccine: report of a collaborative Trans-Tasman workshop.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/253823519fea0f8fd218a73c0bc46803"><gtr:id>253823519fea0f8fd218a73c0bc46803</gtr:id><gtr:otherNames>Moreland NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5458c9dba1fcc8.48707529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1892AD2C-4EF4-4007-AA36-35C378C4CD63</gtr:id><gtr:title>Hepatocellular carcinoma: Review of disease and tumor biomarkers.</gtr:title><gtr:parentPublicationTitle>World journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1cdc194007746faad998b8d68b45b4f6"><gtr:id>1cdc194007746faad998b8d68b45b4f6</gtr:id><gtr:otherNames>Kim JU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>585d6446b66188.56326222</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>876A17C4-8D3C-402D-BB3A-254114877D3B</gtr:id><gtr:title>(99m)Tc SPECT imaging agent based on cFLFLFK for the detection of FPR1 in inflammation.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/414503dcfa8825708ac78a77d4cc1b78"><gtr:id>414503dcfa8825708ac78a77d4cc1b78</gtr:id><gtr:otherNames>Stasiuk GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn><gtr:outcomeId>56caeae99520c7.41788211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C932C95C-95BC-422B-AA2E-0C06357A0475</gtr:id><gtr:title>S117 RSIV. F/HN-mediated gene therapy enables lungs to produce therapeutically relevant levels of FVIII</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42f5800291845f7353b10c7923c91fd6"><gtr:id>42f5800291845f7353b10c7923c91fd6</gtr:id><gtr:otherNames>Pytel K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>585d6c0b0134e7.35079485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15581442-8145-4186-9141-AC7ACCD14779</gtr:id><gtr:title>Cystic Fibrosis Gene Therapy in the UK and Elsewhere.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a009e137431ad6368363564a4ceb3ebc"><gtr:id>a009e137431ad6368363564a4ceb3ebc</gtr:id><gtr:otherNames>Griesenbach U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>5675e1cd501eb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1F493F1-9B26-47C0-909F-CFB637CFF680</gtr:id><gtr:title>Cell tracking technologies for acute ischemic brain injury.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9306a08651e80fb482a0da827344b903"><gtr:id>9306a08651e80fb482a0da827344b903</gtr:id><gtr:otherNames>Gavins FN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>58c1871a2d6921.56066139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62A5E281-AD12-42A1-B1A2-66C73B4F90B5</gtr:id><gtr:title>Hepatic steatosis and fibrosis: Non-invasive assessment.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/417fd662a7e37a22ce884b7d3d4658c6"><gtr:id>417fd662a7e37a22ce884b7d3d4658c6</gtr:id><gtr:otherNames>Karanjia RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>588b5e8117a240.10923709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE6275D6-78CB-4657-A46F-E431ED17086F</gtr:id><gtr:title>Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG.</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9319a69002ca198f3bdf3dd730d8501"><gtr:id>f9319a69002ca198f3bdf3dd730d8501</gtr:id><gtr:otherNames>Reglinski M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn><gtr:outcomeId>56dd5671122506.44315665</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DAC94C1-3A93-4BED-86AE-F2F798F6E562</gtr:id><gtr:title>Clinical Safety and Feasibility of the Advanced Bolus Calculator for Type 1 Diabetes Based on Case-Based Reasoning: A 6-Week Nonrandomized Single-Arm Pilot Study.</gtr:title><gtr:parentPublicationTitle>Diabetes technology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/737dc67cf5b1bf6767f0840fdad1f1e1"><gtr:id>737dc67cf5b1bf6767f0840fdad1f1e1</gtr:id><gtr:otherNames>Reddy M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1520-9156</gtr:issn><gtr:outcomeId>5a6f04f7ef1fb5.52846101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1CA8932-521F-43FB-9704-62495BBF0F89</gtr:id><gtr:title>Prevention of Liver Fibrosis and Cancer in Africa: The PROLIFICA project--a collaborative study of hepatitis B-related liver disease in West Africa.</gtr:title><gtr:parentPublicationTitle>South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3f1a3302ec4c92299242b907f8f829e"><gtr:id>a3f1a3302ec4c92299242b907f8f829e</gtr:id><gtr:otherNames>Howell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>585d5817a3ab67.26086762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A42AFE1-6EEA-49C9-9834-99575E39C512</gtr:id><gtr:title>An Advanced Bolus Calculator for Type 1 Diabetes: System Architecture and Usability Results.</gtr:title><gtr:parentPublicationTitle>IEEE journal of biomedical and health informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b5cedac6b7e9555e1ab1e3478dd20e4"><gtr:id>6b5cedac6b7e9555e1ab1e3478dd20e4</gtr:id><gtr:otherNames>Pesl P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-2194</gtr:issn><gtr:outcomeId>585d5ff49affd3.27406094</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BEA586E-48CA-4C74-AD5C-1D523AADD157</gtr:id><gtr:title>MAP4K4 MEDIATES CARDIOMYOCYTE CELL DEATH AND POTENTIATES A HEART FAILURE PHENOTYPE</gtr:title><gtr:parentPublicationTitle>Heart</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92a63382ddc411bbe0b7a62f1cc63a5d"><gtr:id>92a63382ddc411bbe0b7a62f1cc63a5d</gtr:id><gtr:otherNames>Fiedler L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5675f18043ca9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC2E5AAA-0499-4865-9D53-BF32EF5D45A1</gtr:id><gtr:title>P0356 : Circulating free tumour DNA concentration is a more useful diagnostic marker than TP53 mutation detection in HBV-related HCC in West African patients</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94b61dccdd6b48bd6c1f8a728fd0df51"><gtr:id>94b61dccdd6b48bd6c1f8a728fd0df51</gtr:id><gtr:otherNames>Knapp S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5a5cce2422ccd4.60190573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>162F5765-B3F3-4295-876B-515109F19E9D</gtr:id><gtr:title>Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices.</gtr:title><gtr:parentPublicationTitle>Diabetes therapy : research, treatment and education of diabetes and related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b4f0081df2716aaa6f07dc5c290eda6"><gtr:id>4b4f0081df2716aaa6f07dc5c290eda6</gtr:id><gtr:otherNames>El-Laboudi AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>58a6dc5c1059a8.95959910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93DAF66D-9D1B-4251-8627-49A934BB2FB9</gtr:id><gtr:title>P84Pathway dissection in cardiac muscle cell death: MAP4K4 as a therapeutic target</gtr:title><gtr:parentPublicationTitle>Cardiovascular Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92a63382ddc411bbe0b7a62f1cc63a5d"><gtr:id>92a63382ddc411bbe0b7a62f1cc63a5d</gtr:id><gtr:otherNames>Fiedler L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5457b1ea1af811.27369568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E413A5C5-4DB1-4891-B9CB-2AC81525E3F7</gtr:id><gtr:title>Gd3+ cFLFLFK conjugate for MRI: a targeted contrast agent for FPR1 in inflammation.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/414503dcfa8825708ac78a77d4cc1b78"><gtr:id>414503dcfa8825708ac78a77d4cc1b78</gtr:id><gtr:otherNames>Stasiuk GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>56caf26d728ec0.78201329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8651C7F2-CD16-49B3-9879-146569DD90E7</gtr:id><gtr:title>The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/414503dcfa8825708ac78a77d4cc1b78"><gtr:id>414503dcfa8825708ac78a77d4cc1b78</gtr:id><gtr:otherNames>Stasiuk GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>545772beb819c2.24799101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EA2E9A2-2813-4029-9FBE-2D855434D262</gtr:id><gtr:title>Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy.</gtr:title><gtr:parentPublicationTitle>Journal of clinical and experimental hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab1798b7af749e16c69c4a7bb999a79d"><gtr:id>ab1798b7af749e16c69c4a7bb999a79d</gtr:id><gtr:otherNames>Shariff MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0973-6883</gtr:issn><gtr:outcomeId>589dcd1f3adeb1.94921956</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D87FA0B5-C908-4368-B518-427BCE729379</gtr:id><gtr:title>12 MAP4K4 as a Therapeutic Target in Cardiomyocyte Death: Novel inhibitors Identified through Pharmacophore Modelling and Virtual Screening</gtr:title><gtr:parentPublicationTitle>Heart</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92a63382ddc411bbe0b7a62f1cc63a5d"><gtr:id>92a63382ddc411bbe0b7a62f1cc63a5d</gtr:id><gtr:otherNames>Fiedler L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5457b1b889c8f7.58308043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6B35A64-2B8B-4E9B-85DF-8461EEB9D7DC</gtr:id><gtr:title>An auto-titrating intelligent oxygen therapy (iO
 
 T) system in COPD patients: A randomised cross-over trial</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47df2a4ee6e5dccbf42d6629da9fe1e7"><gtr:id>47df2a4ee6e5dccbf42d6629da9fe1e7</gtr:id><gtr:otherNames>Moghal M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d72841621619.52818156</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC930877-78E7-45F3-BAD6-99E98B58879B</gtr:id><gtr:title>Cystic fibrosis gene therapy: a mutation-independent treatment.</gtr:title><gtr:parentPublicationTitle>Current opinion in pulmonary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a009e137431ad6368363564a4ceb3ebc"><gtr:id>a009e137431ad6368363564a4ceb3ebc</gtr:id><gtr:otherNames>Griesenbach U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1070-5287</gtr:issn><gtr:outcomeId>585d5daed58c73.87989157</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43B16AD4-499E-49AD-AD63-EDFD2AAE6073</gtr:id><gtr:title>Sulforaphane induces neurovascular protection against a systemic inflammatory challenge via both Nrf2-dependent and independent pathways.</gtr:title><gtr:parentPublicationTitle>Vascular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7318fc42a1b0e08958f5898ee9c34e1a"><gtr:id>7318fc42a1b0e08958f5898ee9c34e1a</gtr:id><gtr:otherNames>Holloway PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1537-1891</gtr:issn><gtr:outcomeId>58c17e3bbf02d4.28937879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F7005A8-2284-4958-ACDE-1540D1BD5A34</gtr:id><gtr:title>Modification of the classical Lancefield assay of group A streptococcal killing to reduce inter-donor variation.</gtr:title><gtr:parentPublicationTitle>Journal of microbiological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9319a69002ca198f3bdf3dd730d8501"><gtr:id>f9319a69002ca198f3bdf3dd730d8501</gtr:id><gtr:otherNames>Reglinski M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-7012</gtr:issn><gtr:outcomeId>5aa007f6adc429.70431930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A12ADDB2-DF88-46EC-BF9D-07CDFA33796A</gtr:id><gtr:title>Abstract PR04: DNA-PK inhibition resensitizes ovarian cancer cells to cisplatin in vivo and is associated with modulation of AKT pathway signaling</gtr:title><gtr:parentPublicationTitle>Clinical Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f5c58908d4e114df448f26b548d740d"><gtr:id>1f5c58908d4e114df448f26b548d740d</gtr:id><gtr:otherNames>Cheraghchi-Bashi-Astaneh A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56df0ccad241c9.30997201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F1B31F9-A68C-4C48-A2AE-4C8B88A98116</gtr:id><gtr:title>Method for automatic adjustment of an insulin bolus calculator: in silico robustness evaluation under intra-day variability.</gtr:title><gtr:parentPublicationTitle>Computer methods and programs in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b48195226a83fab0c38e5093a0adfeb9"><gtr:id>b48195226a83fab0c38e5093a0adfeb9</gtr:id><gtr:otherNames>Herrero P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0169-2607</gtr:issn><gtr:outcomeId>5a6ef12d0ef3a0.30263173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4956DE8A-5691-4DB9-A2D5-165C7167842F</gtr:id><gtr:title>IL-1? reduces tonic contraction of mesenteric lymphatic muscle cells, with the involvement of cycloxygenase-2 and prostaglandin E2.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7cfe1bdaa8f7a0023b8d00b70d6dde6"><gtr:id>e7cfe1bdaa8f7a0023b8d00b70d6dde6</gtr:id><gtr:otherNames>Al-Kofahi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>58c185438b6431.76365478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC9F82E6-5028-463C-A5AF-F65AC7F318B3</gtr:id><gtr:title>Automatic Adaptation of Basal Insulin Using Sensor-Augmented Pump Therapy.</gtr:title><gtr:parentPublicationTitle>Journal of diabetes science and technology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b48195226a83fab0c38e5093a0adfeb9"><gtr:id>b48195226a83fab0c38e5093a0adfeb9</gtr:id><gtr:otherNames>Herrero P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1932-2968</gtr:issn><gtr:outcomeId>5aabc49ce7b1b5.58742179</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94BC96CB-DDFE-4EAD-AB73-1AA213D4F9A7</gtr:id><gtr:title>Reversal of TREM-1 ectodomain shedding and improved bacterial clearance by intranasal metalloproteinase inhibitors.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59ab013663648103e1aa55dbcf6c547e"><gtr:id>59ab013663648103e1aa55dbcf6c547e</gtr:id><gtr:otherNames>Weiss G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>5a578bd2efb4f0.64260250</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4A969C8-8137-4C71-8EC1-7210BDAA67A3</gtr:id><gtr:title>Dalton Discussion 15 - Metal ions in medical imaging: optical, radiopharmaceutical and MRI contrast, 8th-10th September 2014, York.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d9d8e519970e2758bea81a22779efa"><gtr:id>45d9d8e519970e2758bea81a22779efa</gtr:id><gtr:otherNames>Archibald SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn><gtr:outcomeId>56d976cea3f3e9.86678405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B523200F-F0E9-4DC6-953B-EF80C59ECF2D</gtr:id><gtr:title>Modeling Ischemic Stroke In Vitro: Status Quo and Future Perspectives.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7318fc42a1b0e08958f5898ee9c34e1a"><gtr:id>7318fc42a1b0e08958f5898ee9c34e1a</gtr:id><gtr:otherNames>Holloway PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>58c17feb296e48.88571526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8DABEC7-8942-4C41-B81F-38A419984302</gtr:id><gtr:title>Critical differences between two classical surgical approaches for middle cerebral artery occlusion-induced stroke in mice.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a61a24bbe02e6fe7439dafb6897ebe62"><gtr:id>a61a24bbe02e6fe7439dafb6897ebe62</gtr:id><gtr:otherNames>Smith HK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>58c188078cbe30.86530035</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA2D98AC-74CA-481A-8FAA-191864C2117B</gtr:id><gtr:title>Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbf34f42160ac4251e22f80010ba3845"><gtr:id>cbf34f42160ac4251e22f80010ba3845</gtr:id><gtr:otherNames>Cox IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>585d6413790ef4.23647120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89750D82-4E88-4B0B-9C8C-7A74F94C7385</gtr:id><gtr:title>Mouse models of heart failure: cell signaling and cell survival.</gtr:title><gtr:parentPublicationTitle>Current topics in developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32e3695f6a0affde99ac87de83a43464"><gtr:id>32e3695f6a0affde99ac87de83a43464</gtr:id><gtr:otherNames>Fiedler LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>9780123979209</gtr:isbn><gtr:issn>0070-2153</gtr:issn><gtr:outcomeId>545b5013e87d23.89749118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9E89E8D-3100-44C0-99B6-A7E577C24A97</gtr:id><gtr:title>Prevention of Liver Fibrosis and Cancer in Africa: The PROLIFICA project - a collaborative study of hepatitis B-related liver disease in West Africa</gtr:title><gtr:parentPublicationTitle>South African Medical Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3f1a3302ec4c92299242b907f8f829e"><gtr:id>a3f1a3302ec4c92299242b907f8f829e</gtr:id><gtr:otherNames>Howell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5a6f0718191656.94542086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBAAC658-A873-417C-8BE8-20C7DA2A41F1</gtr:id><gtr:title>Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers.</gtr:title><gtr:parentPublicationTitle>World journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aebb643ee71829d65ac4e3c73290657d"><gtr:id>aebb643ee71829d65ac4e3c73290657d</gtr:id><gtr:otherNames>Trovato FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>585d644179c3e6.75607085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C4FEA2E-A12F-4602-A70D-8580570E99A7</gtr:id><gtr:title>Xenon improves neurologic outcome and reduces secondary injury following trauma in an in vivo model of traumatic brain injury.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a7a5614ed04ebd68afbd6d48c2a46d1"><gtr:id>4a7a5614ed04ebd68afbd6d48c2a46d1</gtr:id><gtr:otherNames>Campos-Pires R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn><gtr:outcomeId>56cdc70337d8d2.23944687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12C7E58B-E122-4255-B60A-407C8BF57682</gtr:id><gtr:title>Bionanotechnology. Colloidal nanoparticles as advanced biological sensors.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45fece0ea7c43a747b86e4ad23e3c8a8"><gtr:id>45fece0ea7c43a747b86e4ad23e3c8a8</gtr:id><gtr:otherNames>Howes PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>56cb2245c90454.66006325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D10AFFA0-0FD0-4C2B-AECE-8C88C3E26236</gtr:id><gtr:title>Targeting the annexin 1-formyl peptide receptor 2/ALX pathway affords protection against bacterial LPS-induced pathologic changes in the murine adrenal cortex.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ad70bbfe8ff994540dbb9f88dc3a573"><gtr:id>3ad70bbfe8ff994540dbb9f88dc3a573</gtr:id><gtr:otherNames>Buss NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>58c1891ea512f1.55574505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6833D1EF-CEAD-423B-B2D9-0A4DAA3356F4</gtr:id><gtr:title>A pilot evaluation of a computer-based psychometric test battery designed to detect impairment in patients with cirrhosis.</gtr:title><gtr:parentPublicationTitle>International journal of general medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1e926b5034ac64996e644246f91e574"><gtr:id>f1e926b5034ac64996e644246f91e574</gtr:id><gtr:otherNames>Cook NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1178-7074</gtr:issn><gtr:outcomeId>5a578c5550be54.60991282</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12015</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>